Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Pittsburgh
University of California, San Francisco
Children's Hospital of Philadelphia
M.D. Anderson Cancer Center
Genentech, Inc.
Kura Oncology, Inc.
M.D. Anderson Cancer Center
University Hospital, Bordeaux
Peking University Third Hospital
Incyte Corporation
Bristol-Myers Squibb
University of Colorado, Denver
7 Hills Pharma, LLC
Nammi Therapeutics Inc
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Compass Therapeutics
NRG Oncology
Erasmus Medical Center
Exscientia AI Limited
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
KaliVir Immunotherapeutics
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Pfizer
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NRG Oncology
Hoosier Cancer Research Network
Hoosier Cancer Research Network
AstraZeneca
State University of New York at Buffalo
Telix Pharmaceuticals (Innovations) Pty Limited
Gødstrup Hospital
National Institutes of Health Clinical Center (CC)
Aulos Bioscience, Inc.
AstraZeneca
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Arcus Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
3D Medicines
Dana-Farber Cancer Institute